M. J. Biopharm Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: M. J. Biopharm Private Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $22.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

M. J. Biopharm Private Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $22.4M Trade | TransData Nexus

M. J. Biopharm Private Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $22.4M Total Trade · DGFT Verified

M. J. Biopharm Private Limited is an Indian pharmaceutical exporter with a total trade value of $22.4M across 6 products in 4 therapeutic categories. Based on 476 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Insulin ($18.9M), Meropenem ($2.1M), Imipenem ($678.9K).

M. J. Biopharm Private Limited — Export Portfolio & Destination Treemap

M. J. Biopharm Private Limited pharmaceutical export portfolio — 6 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is M. J. Biopharm Private Limited? — Company Overview & Market Position

M. J. Biopharm Private Limited is a privately held biopharmaceutical company established on June 27, 2002, in Pune, Maharashtra, India. The company is registered under the Corporate Identification Number (CIN) U24234PN2002PTC158855. As of March 31, 2023, M. J. Biopharm reported an authorized share capital of ₹400 million and a paid-up capital of ₹230.06 million. The company specializes in the manufacture of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with a focus on diabetes and endocrine treatments, advanced antibiotics, and advanced diabetes medications.

The company's registered office is located at Plot No. 18, IT Park, Hinjawadi Phase II, Near Emcure Industrial, Pune, Maharashtra, India - 411057. M. J. Biopharm operates manufacturing facilities in Pune and Navi Mumbai, Maharashtra, with a workforce of approximately 524 employees. The company's website is www.mjgroup.co.in.

What Does M. J. Biopharm Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Insulin$18.9M 2

Product Portfolio — Top 6 by Export Value

M. J. Biopharm Private Limited exports 6 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Insulin	Diabetes & Endocrine	$18.9M	378	19.9%	2
2	Meropenem	Advanced Antibiotics	$2.1M	58	0.6%	11
3	Imipenem	Advanced Antibiotics	$678.9K	18	1.3%	6
4	Glibenclamide	Advanced Diabetes Medications	$375.5K	10	0.9%	2
5	Ethambutol	Tuberculosis Medications	$171.1K	6	0.0%	12
6	Pyrazinamide	Tuberculosis Medications	$171.1K	6	0.0%	11

M. J. Biopharm Private Limited exports 6 pharmaceutical products across 4 therapeutic categories with a total export value of $22.4M. The top category is Diabetes & Endocrine (84.4% of portfolio), followed by Advanced Antibiotics (12.4%), indicating a concentrated portfolio with the top 5 products accounting for 99.2% of total export value.

M. J. Biopharm Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

M. J. Biopharm Private Limited operates manufacturing facilities in Pune and Navi Mumbai, Maharashtra. The Pune facility is situated at Plot No. 18, IT Park, Hinjawadi Phase II, Near Emcure Industrial, Pune, Maharashtra, India - 411057. The Navi Mumbai facility is located in the L-7 M.I.D.C. Industrial Area, Navi Mumbai, Maharashtra, India - 410208. These facilities are equipped to produce a range of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, with a specialization in diabetes and endocrine treatments, advanced antibiotics, and advanced diabetes medications.

3Key Leadership

The leadership team at M. J. Biopharm Private Limited includes:

Amol Jashvant Shah: Managing Director, appointed on July 1, 2020.

Dhaval Vipin Vashi: Director, appointed on September 27, 2019.

Kajal Amol Shah: Director, appointed on March 24, 2022.

Pradakshina Goswami: Company Secretary, appointed on June 9, 2023.

Pheroze Kersasp Mistry: Nominee Director, appointed on May 4, 2018.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does M. J. Biopharm Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

M. J. Biopharm Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained regulatory approvals for its finished pharmaceutical formulations, enabling market access in these regions. Specific details regarding regulatory filings, approvals, and market access status are not publicly disclosed. However, the company's focus on high-quality manufacturing practices and adherence to international standards suggest a commitment to meeting the stringent requirements of these markets.

2Emerging Markets

M. J. Biopharm Private Limited has expanded its reach into emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these regions, allowing it to supply essential medicines to underserved populations. By leveraging its expertise in manufacturing and regulatory compliance, M. J. Biopharm continues to strengthen its presence in these emerging markets, contributing to global health initiatives.

3Geographic Strategy

M. J. Biopharm Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

M. J. Biopharm Private Limited has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with U.S. regulatory standards. The company has obtained approvals for its Abbreviated New Drug Applications (ANDAs), allowing it to market its generic pharmaceutical products in the United States. Additionally, M. J. Biopharm has filed Drug Master Files (DMFs) with the FDA, providing detailed information about the manufacturing processes and quality controls of its drug substances. The company's facilities have undergone FDA inspections, demonstrating adherence to Good Manufacturing Practices (GMP). These regulatory achievements underscore M. J. Biopharm's commitment to maintaining high-quality standards and meeting the stringent requirements of the U.S. market.

2WHO & EU GMP

M. J. Biopharm Private Limited has achieved World Health Organization (WHO) prequalification for its manufacturing facilities, indicating compliance with international standards for the production of pharmaceutical products. The company has also obtained European Union Good Manufacturing Practice (EU GMP) certificates, affirming its adherence to EU regulations for pharmaceutical manufacturing. These certifications reflect M. J. Biopharm's dedication to maintaining high-quality manufacturing practices and its capability to supply products to international markets.

M. J. Biopharm Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

M. J. Biopharm Private Limited operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's focus on high-quality manufacturing, adherence to international regulatory standards, and a diverse product portfolio position it favorably in the market. While specific market share data is not publicly available, M. J. Biopharm's strategic initiatives and commitment to quality suggest a competitive standing within the industry.

2Key Differentiators

M. J. Biopharm Private Limited's key differentiators include its specialization in the production of human insulin, analogue insulin, and GLP-1 agents, both as drug substances and formulations. The company's expertise spans from process development and proof of concept to commercial scale and yield optimization. Additionally, M. J. Biopharm offers contract manufacturing services for various packaging formats, including vials, ampoules, cartridges, and disposable pens. These capabilities enable the company to provide comprehensive solutions to its partners and customers.

3Strategic Position

Buyer Due Diligence Brief — Evaluating M. J. Biopharm Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

M. J. Biopharm Private Limited has demonstrated a strong track record in pharmaceutical manufacturing, with a total export value of $22.4 million USD and 476 shipments across six products in four therapeutic categories from 2022 to 2026. The company's portfolio is highly concentrated, with the top five products accounting for 99.2% of total exports. This concentration indicates a focused approach to product development and market penetration. The company's adherence to international regulatory standards, including WHO prequalification and EU GMP certifications, underscores its reliability as a supplier. M. J. Biopharm's commitment to quality and compliance positions it as a dependable partner in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering M. J. Biopharm Private Limited as a supplier:

TransData Nexus Research · FDA, WHO, EMA regulatory databasesMar 2026

Frequently Asked Questions — M. J. Biopharm Private Limited

How many pharmaceutical products does M. J. Biopharm Private Limited export from India?

M. J. Biopharm Private Limited exports 6 pharmaceutical products across 4 therapeutic categories. The top exports are Insulin ($18.9M), Meropenem ($2.1M), Imipenem ($678.9K), Glibenclamide ($375.5K), Ethambutol ($171.1K). Total export value is $22.4M.

What is M. J. Biopharm Private Limited's total pharmaceutical export value?

M. J. Biopharm Private Limited's total pharmaceutical export value is $22.4M, based on 476 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does M. J. Biopharm Private Limited cover?

M. J. Biopharm Private Limited exports across 4 therapeutic categories. The largest are Diabetes & Endocrine (84.4%, 1 products), Advanced Antibiotics (12.4%, 2 products), Advanced Diabetes Medications (1.7%, 1 products).

Get Full M. J. Biopharm Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.